The estimated Net Worth of Brian M. Hahn is at least $1.77 Milhão dollars as of 18 June 2024. Mr. Hahn owns over 17,500 units of GlycoMimetics Inc stock worth over $11,303 and over the last 11 years he sold GLYC stock worth over $359,378. In addition, he makes $1,397,400 as Chief Financial Officer at GlycoMimetics Inc.
Brian has made over 7 trades of the GlycoMimetics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 17,500 units of GLYC stock worth $4,375 on 18 June 2024.
The largest trade he's ever made was buying 20,000 units of GlycoMimetics Inc stock on 11 November 2022 worth over $21,200. On average, Brian trades about 4,096 units every 189 days since 2014. As of 18 June 2024 he still owns at least 70,643 units of GlycoMimetics Inc stock.
You can see the complete history of Mr. Hahn stock trades at the bottom of the page.
Brian Hahn serves as Chief Financial Officer of the Company. Mr. Hahn has served as our Chief Financial Officer and Senior Vice President since January 2019 and was previously our Chief Financial Officer from 2012 until January 2019 and our Director of Finance and Administration from 2010 to 2012. From 2002 to 2009, Mr. Hahn served as Executive Director of Finance at MiddleBrook Pharmaceuticals, Inc., formerly Advancis Pharmaceutical, a specialty pharmaceutical company, and from 2009 to 2010 he served as Assistant Controller for OpGen, Inc., a biotechnology company. From 1998 to 2001, he was a senior accountant with Bering Truck Corporation. Mr. Hahn received a B.B.A. from Shenandoah University and an M.B.A. from the University of Maryland. Mr. Hahn currently serves as Co-Chair of the Biotechnology Industry Organization (BIO)’s Finance and Tax Committee and on the SEC Advisory Committee on Small and Emerging Companies. In 2015, Mr. Hahn testified on behalf of BIO before the House Subcommittee on Capital Markets and Government Sponsored Enterprises in support of the Fostering Innovation Act.
As the Chief Financial Officer of GlycoMimetics Inc, the total compensation of Brian Hahn at GlycoMimetics Inc is $1,397,400. There are 1 executives at GlycoMimetics Inc getting paid more, with Rachel King having the highest compensation of $2,689,070.
Brian Hahn is 45, he's been the Chief Financial Officer of GlycoMimetics Inc since 2012. There are 16 older and no younger executives at GlycoMimetics Inc. The oldest executive at GlycoMimetics Inc is Dr. John L. Magnani, 68, who is the Sr. VP of Research & Chief Scientific Officer.
Brian's mailing address filed with the SEC is C/O GLYCOMIMETICS, INC., 9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.
Over the last 11 years, insiders at GlycoMimetics Inc have traded over $15,299,593 worth of GlycoMimetics Inc stock and bought 10,868,557 units worth $48,421,008 . The most active insiders traders include Scott D Sandell, Peter J Barris, eM James Barrett. On average, GlycoMimetics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $38,210. The most recent stock trade was executed by Public Equities, L.P.Invus ... on 7 August 2024, trading 322,361 units of GLYC stock currently worth $61,249.
at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. since the company’s inception in 2003, we have developed a robust, diversified product pipeline. we are a public company traded on the nasdaq under the symbol glyc.
GlycoMimetics Inc executives and other stock owners filed with the SEC include: